



Aducanumab for Alzheimer’s Disease: Effectiveness and Value

Thursday • July 15, 2021 • 9:00 am to 4:00 pm PT

Virtual Event – Zoom Webinar

Time	Activity
9:00 AM—9:15 AM	Meeting Convened and Opening Remarks Steven D. Pearson, MD, MSc, President, ICER
9:15 AM—10:00 AM	Presentation of the Clinical Evidence Grace A. Lin, MD, University of California, San Francisco
10:00 AM—10:45 AM	Presentation of the Economic Model Melanie Whittington, PhD, MS, ICER
10:45 AM—11:15 AM	Manufacturer Comments and Discussion
11:15 AM—11:45 AM	Public Comments and Discussion
11:45 AM—12:30 PM	Lunch Break
12:30 PM—1:30 PM	CTAF Vote on Clinical Effectiveness and Value
1:30 PM—1:45 PM	Break
1:45 PM—3:30 PM	Policy Roundtable
3:30 PM—4:00 PM	Reflections from CTAF
4:00 PM	Meeting Adjourned

ICER Staff and Consultants	
Jonathan D. Campbell, PhD, MS,* Senior Vice President for Health Economics, ICER	Steven D. Pearson, MD, MSc,* President, ICER
Laura Cianciolo,* Program Manager, ICER	David M. Rind, MD, MSc,* Chief Medical Officer, ICER
Noemi Fluetsch, MSc, MPH,* Research Assistant, Health Economics and Outcomes Research, ICER	Patricia G. Synnott, MS, MALD,* Senior Manager, CEA Registry and Global Health Initiatives, Center for the Evaluation of Value and Risk in Health
Grace A. Lin, MD,* Associate Professor of Medicine and Health Policy, UCSF	Azanta Thakur,* Program and Event Coordinator, ICER
Avery McKenna,* Research Assistant III, Evidence Synthesis, ICER	Melanie D. Whittington, PhD, MS,* Associate Director of Health Economics, ICER
Emily Nhan,* Research Assistant, ICER	

*No conflicts of interest to disclose, defined as individual health care stock ownership (including anyone in the member’s household) in any company with a product under study, including comparators, at the meeting in excess of \$10,000 during the previous year, or any health care consultancy income from the manufacturer of the product or comparators being evaluated.

Participating Members of CTAF	
Ralph G. Brindis, MD, MPH, MACC, FSCAI, FAHA,* Clinical Professor of Medicine, UCSF	Annette Langer-Gould, MD, PhD,* Regional Lead for Clinical and Translational Neuroscience, Southern California Permanente Medical Group, Kaiser Permanente; Practicing Multiple Sclerosis Specialist, Los Angeles Medical Center
Felicia Cohn, PhD,* Bioethics Director, Kaiser Permanente, Orange County; Clinical Professor of Bioethics, Department of Medicine, University of California, Irvine School of Medicine	Sei Lee, MD,* Associate Professor of Medicine, Division of Geriatrics, UCSF
Sanket Dhruva, MD, MHS, FACC,* Assistant Professor of Medicine, UCSF	Elizabeth J. Murphy, MD, DPhil,* Professor of Clinical Medicine, UCSF; Chief, Division of Endocrinology and Metabolism, Zuckerberg San Francisco General Hospital
Rena K. Fox, MD,* (Chair) Professor of Medicine, UCSF	Kathryn A. Phillips, PhD,* Professor of Health Economics and Health Services Research; Director and Founder, UCSF Center for Translational and Policy Research on Personalized Medicine; Department of Clinical Pharmacy/School of Pharmacy, UCSF Institute for Health Policy Studies, and UCSF Comprehensive Cancer Center
Bob Collyar,* Patient Advocate in Research	Ann Raldow, MD, MPH,* Assistant Professor, Department of Radiation Oncology, UCLA David Geffen School of Medicine
Jeffrey Hoch, PhD,* Associate Director, Center for Healthcare Policy and Research, UC Davis	Richard Seiden, JD,* Patient Advocate, Retired Partner, Foley & Lardner LLP
Jeffrey Klingman, MD,* Chief of Neurology, Kaiser Permanente, Walnut Creek	Anthony Sowry,* Patient Advocate and Lead Volunteer, National Patient Advocate Foundation; Senior Vice President, Maritime Container Shipping (Retired)

*No conflicts of interest to disclose, defined as individual health care stock ownership (including anyone in the member's household) in any company with a product under study, including comparators, at the meeting in excess of \$10,000 during the previous year, or any health care consultancy income from the manufacturer of the product or comparators being evaluated.

Policy Roundtable Participant	Conflicts of Interest
Matthew Baumgart , Vice President of Health Policy, Alzheimer's Association	The Association received 0.89% of its total 2020 contributed revenue from the biotechnology, pharmaceutical, diagnostics, and clinical research industry, including 0.15% from Biogen and Eisai.
Leslie Fish, RPh, PharmD , Vice President of Clinical Pharmacy, IPD Analytics	Leslie Fish is an employee of IPD Analytics.
Patrick Gleason, PharmD , Assistant Vice President, Health Outcomes, Prime Therapeutics	Patrick Gleason is an employee of Prime Therapeutics.
Victor W. Henderson, MD, MS , Professor, Epidemiology and Population Health and Neurology and Neurological Sciences; Director, Alzheimer's Disease Research Center, Stanford University	No conflicts of interest to disclose.
Laura Jones , Caregiver and Advocate	No conflicts of interest to disclose.
Sarah Kremen, MD , Director, Neurobehavior Program, Jona Goldrich Center for Alzheimer's and Memory Disorders, Cedars-Sinai Medical Center	Sarah Kremen served as a site PI for aducanumab trials PRIME and ENGAGE.
Chris Leibman, PharmD, MS , Head of Value and Access, Biogen	Chris Leibman is an employee of Biogen.
Mark McClellan, MD, PhD , Director, Duke University Margolis Center for Health Policy	Receipt of monetary value, including salary and other payments for services. Equity interests in individual stocks, stock options, or other ownership interests in excess of \$10,000. Status as an officer, board member, trustee, owner, or employee of a health care company, or an organization that receives more than 25% of its funding from health care companies.